Related Experiment Video
Updated: Jun 20, 2026
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
CD24 overexpression in cancer development and progression: a meta-analysis
Ju-Han Lee1, Seo-Hee Kim, Eung-Seok Lee
1Department of Pathology, The Bioinformatics Interest Group, Korea University Ansan Hospital, Gyeonggi-Do 425-707, Korea.
Oncology Reports
|September 30, 2009
Summary
CD24 protein is frequently overexpressed in various cancers, correlating with advanced stages and poorer survival. This meta-analysis confirms CD24 as a significant marker of malignancy and a poor prognostic factor across multiple cancer types.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- CD24 is recognized as a potential oncogene and a promoter of cancer metastasis.
- Controversy exists regarding CD24's role as a prognostic factor for adverse outcomes in human cancers.
- Understanding CD24's expression patterns and prognostic significance is crucial for cancer patient management.
Purpose of the Study:
- To resolve the controversy surrounding CD24 expression as a prognostic indicator in various carcinomas.
- To systematically evaluate the association between CD24 expression and prognostic parameters, including overall survival.
- To determine the frequency and significance of CD24 overexpression in different cancer types.
Main Methods:
- A meta-analysis was conducted on studies published between 1990 and 2009.
- Twenty-eight studies comprising 2,925 cases were reviewed based on predefined selection criteria.
- Effect sizes for prognostic parameters and overall survival were calculated using odds ratios (OR) and hazard ratios (HR).
Main Results:
- CD24 was overexpressed in 68% of analyzed carcinomas, significantly more than in benign lesions (OR=4.21).
- CD24 overexpression correlated with lymph node metastasis (OR=2.41), advanced clinical stages (OR=1.59), and shortened overall survival (HR=2.13).
- Specific associations were noted in breast cancer (lymph node metastasis, advanced stages, lymphovascular invasion), urothelial carcinomas, and endometrial adenocarcinomas (higher grades).
Conclusions:
- The meta-analysis provides strong evidence that CD24 is a significant marker of malignancy and poor prognosis in diverse carcinomas.
- CD24 overexpression is particularly linked to adverse outcomes in breast, ovarian, and urothelial cancers.
- CD24 may play a critical role in the development and progression of these cancers.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...